Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Pujol

Showing results (141-150 of 155) with videos related to

Pageof 16
Sort By:
British Journal of Cancer|May 20, 2004
CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patientsJ-L Pujol, O Molinier, W Ebert, et al.
Journal of the National Cancer Institute|February 22, 2001
Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized studyJ L Pujol, J P Daurès, A Rivière, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III studyJ L Pujol, J Y Douillard, A Rivière, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2003
Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancerE Quoix, B Lebeau, A Depierre, et al.
Lung Cancer (Amsterdam, Netherlands)|August 5, 2014
Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trialsG V Scagliotti, C Gridelli, F de Marinis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 3, 2005
Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatinJ-L Pujol, J-L Breton, R Gervais, et al.
Bulletin Du Cancer|May 1, 1996
[Results of a randomized study comparing combination of navelbine-cisplatin to combination of vindesine-cisplatin and to navelbine alone in 612 patients with inoperable non-small cell lung cancer]T Le Chevalier, D Brisgand, J L Pujol, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 24, 2011
Third CECOG consensus on the systemic treatment of non-small-cell lung cancerT Brodowicz, T Ciuleanu, J Crawford, et al.
Lung Cancer (Amsterdam, Netherlands)|December 18, 2004
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomesT Le Chevalier, G Scagliotti, R Natale, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2015
Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†J-L Pujol, A Lavole, E Quoix, et al.
Pageof 16

Showing results (141-150 of 155) with videos related to

Sort By:
Pageof 16
British Journal of Cancer|May 20, 2004
CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patientsJ-L Pujol, O Molinier, W Ebert, et al.
Journal of the National Cancer Institute|February 22, 2001
Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized studyJ L Pujol, J P Daurès, A Rivière, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III studyJ L Pujol, J Y Douillard, A Rivière, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2003
Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancerE Quoix, B Lebeau, A Depierre, et al.
Lung Cancer (Amsterdam, Netherlands)|August 5, 2014
Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trialsG V Scagliotti, C Gridelli, F de Marinis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 3, 2005
Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatinJ-L Pujol, J-L Breton, R Gervais, et al.
Bulletin Du Cancer|May 1, 1996
[Results of a randomized study comparing combination of navelbine-cisplatin to combination of vindesine-cisplatin and to navelbine alone in 612 patients with inoperable non-small cell lung cancer]T Le Chevalier, D Brisgand, J L Pujol, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 24, 2011
Third CECOG consensus on the systemic treatment of non-small-cell lung cancerT Brodowicz, T Ciuleanu, J Crawford, et al.
Lung Cancer (Amsterdam, Netherlands)|December 18, 2004
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomesT Le Chevalier, G Scagliotti, R Natale, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2015
Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†J-L Pujol, A Lavole, E Quoix, et al.
Pageof 16